Buprenorphine: a guide for nurses
Effectiveness bank home page. Opens new windowAbstract

This entry is for a document added to the Effectiveness Bank but not fully analysed. Usually the entry consists only of the reference and an edited version of the original abstract, with either no commentary from Drug and Alcohol Findings or only essential points. The original document was not published by Findings; click Title to order a copy.

Links to other documents. Hover over for notes. Click to highlight passage referred to. Unfold extra text Unfold supplementary text
Copy title and link | Comment/query |

Buprenorphine: a guide for nurses.

Azimi-Bolourian S., Fornili K.
[US] Substance Abuse and Mental Health Services Administration, 2009.
Unable to obtain a copy by clicking title? Try this alternative source.

Comprehensive guide from the US health department’s substance use treatment authority for nurses involved in buprenorphine-based treatment for dependence on opiate-type drugs like heroin, including detoxification and substitute prescribing.

Summary This guide from the US health department’s substance use treatment authority is intended to provide nurses with general information about buprenorphine products (including the combination of buprenorphine and naloxone marketed as Suboxone), with a view to improving treatment outcomes for patients receiving treatment for dependence on opioid drugs (opiate-type drugs like heroin). Buprenorphine medications are commonly used to aid withdrawal from opioids, and on a long-term maintenance basis as a safer substitute for illegal opioids.

Report cover: click to download full report

The guide can serve as a resource for specialist nurses in substance use services and for those working with general practitioners and in other community settings. As well as comprehensive guidance, it includes reproducible resources such as screening and assessment questionnaires and schedules to identify and diagnose substance use and mental health problems, treatment process flowcharts, and dosing schedules.

The intention is that the guidance will fulfil the following learning objectives:
• Provide nurses with general information on the pharmacology, safety profile, adverse effects, interactions, cautions, contraindications, and abuse potential of buprenorphine products.
• Increase nurses’ factual knowledge on protocols for the use of buprenorphine products in medically supervised withdrawal (detoxification) and maintenance treatment services.
• Help nurses, in conjunction with physicians, design strategies for providing comprehensive physical and psychosocial assessments, treatment monitoring, and appropriate referral for opioid addiction and co-occurring medical and psychiatric conditions.
• Provide comprehensive and practical guidance for patient screening, assessment, starting treatment and the early induction phase, stabilisation, and preventing buprenorphine causing sudden withdrawal symptoms by displacing stronger opiate-type drugs from neural receptors in the body.
• Educate nurses about effective communication, assessing patients’ readiness to change, and appropriate motivational enhancement interventions to ensure that counselling is delivered concurrently with pharmacological interventions.
• Enhance addiction recovery management by educating nurses about stigma, patient empowerment, how medical staff and patients can work towards recovery in partnership, evidence-based practices, the application of technology, and the importance of ongoing patient monitoring and support.

Last revised 22 October 2015. First uploaded 22 October 2015

Open Effectiveness Bank home page

Top 10 most closely related documents on this site. For more try a subject or free text search

DOCUMENT 2017 Drug misuse and dependence: UK guidelines on clinical management

DOCUMENT 2011 Buprenorphine/naloxone for opioid dependence: clinical practice guideline

ABSTRACT 2011 Guidance for the use of substitute prescribing in the treatment of opioid dependence in primary care

REVIEW 2009 Pharmacotherapies for the treatment of opioid dependence: efficacy, cost-effectiveness and implementation guidelines

DOCUMENT 2015 American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use

DOCUMENT 2009 Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence

REVIEW 2012 BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP

STUDY 2011 Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence

STUDY 2010 Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial

DOCUMENT 2018 Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families: Treatment Improvement Protocol: TIP 63